Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5605470 | International Journal of Cardiology | 2017 | 6 Pages |
Abstract
Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. Recently, new applications for this therapy have been investigated. This article reviews alternative uses for TMZ in non-coronary artery diseases, such as non-ischemic cardiomyopathy, sepsis, myocardial dysfunction induced by anti-cancer drugs, diabetic cardiomyopathy and contrast-induced nephropathy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Hai Zou, Xing-Xing Zhu, Ya-Hui Ding, Qin-Yang Jin, Lin-Yan Qian, Dong-Sheng Huang, Xue-Jiang Cen,